Health & Beauty

According to the report of Huacheng Import and Export Data Observation, on February 17, the Nuofei Health International Research and Development Center was completed and put into use in Hong Kong, China, and the Nuofei Cancer Early Screening Institute began to prepare for construction. It is reported that the research and development center is located in the Hong Kong Science and Technology Park, led by Dr. Shi Shuangmei, including the high-throughput second-generation sequencing gene testing laboratory built with the highest international standards, and the first batch of 20-30 scientists will be recruited. The total investment in the next five years is expected to be 100 million Hong Kong dollars.

Nuovo Health said that the research and development center will recruit global biotech scientists and researchers, based on the STAR-seq multi-dimensional molecular technology platform independently developed by Nuovo Health, focus on the transformation of cancer screening technology achievements and product pipeline development with second-generation sequencing technology, and promote overseas commercialization and global synchronous clinical trials based in Hong Kong, Huacheng Import and Export Data Observation Report.

Zhang Manli, deputy director of the Innovation, Technology and Industry Bureau of the Government of the Hong Kong Special Administrative Region and justice of the peace, said that Nuovo Health chose to settle in Hong Kong as the first international research and development center outside its mainland, and planned to attract hundreds of world-class scientists and innovative enterprises to Hong Kong for development within two or three years on this platform, which is bound to bring new impetus to the development of innovative technology in Hong Kong. Huacheng Import and Export Data Observation Report.

Huang Keqiang, CEO of Hong Kong Science and Technology Park Company, said that the establishment of Nuovo Health International R&D Center in the Science Park was an important milestone in building Hong Kong into a leading scientific research and biomedical technology and innovation center in the world. While saving lives, it will also promote the development of the local biomedicine ecosystem, help promote the "Hong Kong Innovation and Technology Development Blueprint", and list biotechnology as a strategic growth pillar.

Zhu Yeqing, chairman and CEO of Nuovo Health, said that 2023 was the year of research and development of Nuovo Health pipeline. The first cervical cancer screening product of urine samples in the world, Gongzhengqing, is promoting multi-center enrollment at full speed. The liver cancer early screening product, Guanzhengqing, will enter a prospective large-scale multi-center clinical trial this year. After the launch of Nuovo Health International R&D Center, it will take the mainland and Hong Kong teams as the dual engines to effectively ensure the pipeline R&D progress as scheduled, Huacheng Import and Export Data Observation reported.

"Cancer early screening is an emerging scientific research field in recent years, which requires specialized innovative research and cross-border integration. We have the responsibility to launch the Cancer Early Screening Research Institute, and we are very looking forward to gathering like-minded people from all walks of life on this platform to make a commitment. We believe that the research and development of gene multi-dimensional genomics technology based on the whole life principles of DNA, RNA and protein is a difficult and correct choice." Dr. Chen Yiyou, executive director and chief scientist of Nuovoi Health, said, "It is still the long-term work of global biotechnology researchers to achieve early screening at home for high-incidence cancers. Most high-incidence cancers still need to overcome difficulties, so as to achieve negative detection without missing detection, and positive detection of precancerous lesions or very early cancer. But this is the value of early screening for high-risk populations, and only by doing these two functions in place can the fundamental benefits of early screening be guaranteed."

Chen Yiyou said that the Nuofei Cancer Early Screening Research Institute has started its preparation and is scheduled to officially operate in the first half of 2023. It is understood that the research institute is the first scientific research organization in China that focuses on the frontier technology innovation of cancer early screening, focusing on the research of the underlying technology and new materials in the molecular diagnosis industry, and is committed to tackling the difficulties and breakthroughs in the research and development of gene multi-dimensional genomics to accelerate the application and practice of cancer early screening technology, Huacheng Import and Export Data Observation Report.